Epidermal Radionuclide Therapy: Dermatological High-Dose-Rate Brachytherapy for the Treatment of Basal and Squamous Cell Carcinoma

  • Cesidio Cipriani
  • Antioco F. Sedda
Part of the Medical Radiology book series (MEDRAD)


Non-melanocytic skin cancer (NMSC) is the most frequent malignancy among populations of European origin, and in some countries it accounts for about half of all tumours. In the present paper a therapeutic option for the treatment of Basal CellCell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) is described. It basically consists in a superficial high dose brachytherapy, characterised by the use of radioactive beta emitting isotopes, incorporated in a specially formulated inert, synthetic resin, which is applied on the surface of skin tumours. The electrons from high energy (> 1MeV) beta emitters isotopes deposit more than 90 % of the dose to the first 2 mm of the skin, which is the depth usually interested from tumour invasion, but spare the deeper tissues from irradiation. The therapy has been used in a large variety of BCC and SCC: tumours of very large sizes, relapsing or recurrent forms, multifocal lesions, without restriction of site, dimension, clinical or histological type, patients clinical situation. A complete response was obtained in 95% of the treated lesions, and in 84 % of the lesions after a single application. A clear advantage of the proposed nuclear medicine therapeutic treatment with respect to the surgery is especially evident for all the tumours located in difficult sites, on which surgery would be difficult (nose, ears) or would produce functional mutilations (penis, vulva, eyelids)


Squamous Cell Carcinoma Basal Cell Carcinoma Actinic Keratosis Beta Emitter Nevoid Basal Cell Carcinoma Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. American Cancer Society (2008) Cancer facts and figures. ACS, Atlanta.
  2. Astner S, Dietterle S, Otberg N, Röwert-Huber HJ, Stockfleth E, Lademann J (2008) Clinical applicability of in vivo fluorescence confocal microscopy for noninvasive diagnosis and therapeutic monitoring of nonmelanoma skin cancer. J Biomed Opt 13(1):014003Google Scholar
  3. Beauleu Lacoste I, Joly P, Ruto F, Thomine F, Fusade T, Chevaillier B, Ortoli JC, Lauret P (1993) Metastatic basal cell carcinoma. Ann Dermatol Venerol 120(2):135–138Google Scholar
  4. Bianchi L, Orlandi A, Campione E (2004) Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol 151:148–56Google Scholar
  5. Cassarino DS, Derienzo PD, Barr RJ (2006) Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification-part II. J Cutan Pathol 33(4):261–279Google Scholar
  6. Chan S, Dhadda AS, Swindell R (2007) Single fraction radiotherapy for small superficial carcinoma of the skin, Clin Oncol (R Coll Radiol) 19(4):256–259Google Scholar
  7. Cornell RC, Greenway HT, Tucker SB et al (1992) Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 26:117–120Google Scholar
  8. Fleming I, Amonette MD, Managhan T, Fleming I (1995) Principles of management of basal and squamous cell carcinoma of the skin. Cancer 75 (suppl no 2):699–704Google Scholar
  9. Gallagher RP, Hill GB, Bajdik CD et al (1995) Sunlight exposure, pigmentary factors, and risk of non melanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol 131:157–163Google Scholar
  10. Garcia L, Nagore E, Llombart B, Sanmartin O, Botella-Estrada R, Requena C, Jorda E, Guillen C (2006) Basal cell carcinoma of the nasolabial fold: an apparently ‘benign’ tumour that often needs complex surgery. J Eur Acad Dermatol Venereol 20(8):926–930PubMedCrossRefGoogle Scholar
  11. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW (2004) Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64(21):7985–7994PubMedCrossRefGoogle Scholar
  12. Geisse J, Caro I, Lindholm J (2004) Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle controlled studies. J Am Acad Dermatol 50:722–733Google Scholar
  13. Goldberg LH (1996) Basal cell carcinoma. Lancet 347:663–667PubMedCrossRefGoogle Scholar
  14. Guo HR, Yu HS, Hu H, Monson RR (2001) Arsenic in drinking water and skin cancers: Cell type specificity (Taiwan, ROC). Cancer Causes Control 12:909–916PubMedCrossRefGoogle Scholar
  15. Jemec JB, Holm EA (2003) Non-melanoma skin cancer in organ transplant patients. Transplantation 75:253–257PubMedCrossRefGoogle Scholar
  16. Lawrence N, Cottel WI (1994) Squamous cell carcinoma of skin with perineural invasion. J Am Acad Dermatol 31(1):30–33PubMedCrossRefGoogle Scholar
  17. Lee K, McKean ME, McGregor IA (1985) Metastatic patterns of squamous carcinoma in the parotid lymph nodes. Br J Plast Surg 38(1):6–10PubMedCrossRefGoogle Scholar
  18. Lichter MD, Karagas MR, Mott LA, Spencer SK, et al (2000) Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. Arch Dermatol 136:1007–1011Google Scholar
  19. Margoob AA (1997) Basal and squamous cell carcinomas: what every primary care physician should know. Postgrad Med 102:139–159Google Scholar
  20. Martinez JC, Otley CC (2001) The management of melanoma and non-melanoma skin cancer: a review for the primary care physician. Mayo Clinic Proc 76(1253):63Google Scholar
  21. Nijsten TE, Stern RS (2003) The increased risk of skin cancer is persistent after discontinuation of psoralen + ultraviolet A: a cohort study. J Invest Dermatol 121:252–258PubMedCrossRefGoogle Scholar
  22. Oseroff AR, Blumenson LR, Wilson BD, Mang TS, Bellnier DA, Parsons JC, Frawley N, Cooper M, Zeitouni N, Dougherty TJ (2006) A dose ranging study of photodynamic therapy with porfimer sodium (Photofrin) for treatment of basal cell carcinoma. Lasers Surg Med 38(5):417–426Google Scholar
  23. Peng Q, Warloe T, Berg K et al (1997) %-Aminolevulinic acid-based photodynamic theraphy: clinical research and future challenges. Cancer 79:2282–2308Google Scholar
  24. Peris K, Campione E, Micantonio T (2005) Imiquimod treatment of superficial and nodular basal cell carcinoma: 12 week open label trial. Dermatol Surg 31:318–323Google Scholar
  25. Petrovic D, Visnjic M, Mihailovich D, Petrovic S, Pesic Z (2004) Margin size in basocellular skin carcinoma resection: impact on relapse. Acta Fac Med Naiss 21(4):195–200Google Scholar
  26. Postelthwaith KR, Courteney DJ, Gosney JR (1993) Basal cell carcinoma with hepatic metastases. J Oral Maxillofac Surg 50:670–673Google Scholar
  27. Sauermann K, Gambichler T, Wilmert M, Rotterdam S, Stücker M, Altmeyer P, Hoffmann K (2002) Investigation of basal cell carcionoma by confocal laser scanning microscopy in vivo. Skin Res Technol 8(3):141–147Google Scholar
  28. Sedda AF, Rossi G, Cipriani C (2003) Beta emitter multilayer for the dermatological brachytherapy of cutaneous tumours. European Association of Nuclear Medicine—Annual congress, AmsterdamGoogle Scholar
  29. Sedda AF, Rossi G, Cipriani C, Carrozzo AM, Donati P (2007) Dermatological beta brachytherapy of basal and squamous cell carcinoma. 21st world congress of dermatology, Buenos Aires, 30 Sept–5 OctGoogle Scholar
  30. Sedda AF, Rossi G, Cipriani C, Carrozzo AM, Donati P (2008) Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma. Clin Exp Dermatol 33(6):745–749PubMedCrossRefGoogle Scholar
  31. Shimm DS, Wilder RB (1991) Radiation therapy for squamous cell carcinoma of the skin. Am J Clin Oncol 14:383–386PubMedCrossRefGoogle Scholar
  32. Tran H, Chen K, Shumack S (2003) Epidemiology and aetiology of basal cell carcinoma, Br J Dermatol 149(Suppl 66):50–52Google Scholar
  33. Tavin E, Persy MS, Jacobs J (1995) Metastatic basal cell carcinoma of the head and neck. Laryngoscope 105(8PH1):814–817Google Scholar
  34. Triesscheijn M, Ruevekamp M, Antonini N, Neering H, Stewart FA, Baas P (2006) Optimizing meso-tetra-hydroxyphenyl-chlorin mediated photodynamic therapy for basal cell carcinoma. Photochem Photobiol 6:1686–1690Google Scholar
  35. Vun Y, Siller G (2006) Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study. Australas J Dermatol 47(3):169–171PubMedCrossRefGoogle Scholar
  36. Wilder RB, Kittelson JM, Shimm DS (1991) Basal cell carcinoma treated with radiation therapy. Cancer 68:2134–2137Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Nuclear Medicine DepartmentS. Eugenio HospitalRomeItaly
  2. 2.Physics and New Materials DepartmentENEA - CasacciaRomeItaly

Personalised recommendations